Durvalumab with bevacizumab adjuvant therapy for treating newly diagnosed hepatocellular carcinoma at high risk of recurrence after curative therapy

Durvalumab with bevacizumab is intended to treat hepatocellular carcinoma (HCC), the most
common type of liver cancer, where there is a high risk of the cancer returning after curative
treatment. It is common that people with HCC are asymptomatic (do not show symptoms related
to the cancer). There is increased risk of developing HCC if you have underlying liver disease (e.g.,
hepatitis B/C or non-alcoholic fatty liver disease), or cirrhosis (scarring of the liver).